banner
LightNews LightNews
katesears.bsky.social
Kate Sears
@katesears.bsky.social
1.6K followers 860 following 460 posts
Hi I'm Kate, community lead for Medical.watch. Want practice changing updates in oncology/hematology? Get our weekly newsletter and join 2700+ clinicians. Subscribe for free: Medical.watch About us: tinyurl.com/Medicalwatch
Posts Media Videos Starter Packs
Pinned
katesears.bsky.social
Kate Sears @katesears.bsky.social · Nov 17
Hello #MedSky and #OncSky!

My name's Kate and I'm community lead for Medical.watch, a free newsletter for oncology/hematology professionals.

Our story is here: www.resources.medical.watch/post/why-we-...

I love to post SUPER COOL videos...like this one!
3 3 33
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 19
🟡 Single-arm studies with strong biomarker rationale can drive approvals
🟣 Tumor-agnostic evidence, early-line trials & RWE must be included—or we risk undervaluing #PrecisionOncology

#EvidenceBasedMedicine #CancerResearch #ClinicalTrials #PersonalizedMedicine

ascopubs.org/doi/10.1200/...
Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review
ascopubs.org
1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 19
💫🌟🔥 Hot off the press (Comments & Controversies)🌟💫

Thrilled to see the timely piece

👉 “Precision Oncology and Modernizing Evidence Standards”

🔑 Key takeaways:
🔵 RCT-only frameworks miss the reality of #PrecisionMedicine
🟢 Basket, umbrella & N-of-1 trials are cornerstones of #PrecisionOncology
1 1 2
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 18
Can't wait Andrea! 🙂
1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 18
🚨 NEJM | Sept 2025
Low-dose aspirin in PI3K-altered localized #ColorectalCancer (ALASCCA)

“Low-dose aspirin cut 3-yr recurrence by ~50% in PI3K-altered localized colorectal cancer.”
www.nejm.org/doi/full/10....
www.nejm.org
1 3
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 17
#Immunotherapy #IOtoxicities
aacrjournals.org/cancerrescom...
Immune activation signatures associated with fatigue in cancer patients undergoing immune checkpoint inhibitor therapy
Abstract. Fatigue is a common and often debilitating adverse event among patients receiving immune checkpoint inhibitor (ICI) therapy, yet its underlying immunologic mechanisms remain poorly defined. ...
aacrjournals.org
1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 17
💫🌟🎓🆕Immune activation & ICI-related fatigue
New study (JHU + Genentech)

✅ 58.5% of pts on ICIs reported fatigue
✅ Fatigue linked to ↑ Th1 cytokines (IFN-γ, IL-2, IL-12)
✅ Expansion of CD8+ effector T cells
✅ Fatigue = surrogate of immune activation
1 1 1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 16
✅ GA captured frailty & comorbidities beyond routine clinical eval
⚖️ Supports tailored therapy for older/frail MM pts

#GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #MultipleMyeloma

www.geriatriconcology.net/article/S187...
Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma
Impressive therapeutic progress has been obtained in multiple myeloma (MM) due to the introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and, more recently, T-cell r...
www.geriatriconcology.net
2
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 16
🧓👵 Geriatric assessment vs clinical evaluation in MM
J Geriatr Oncol (Sept 2025, Raddoux et al.)
👏 Congrats to the authors & to the #GeriOnc community advancing care for older #MM patients.

📊 Prospective study in 200 older adults w/ newly diagnosed #MultipleMyeloma
1 1 2
Reposted by Kate Sears
bloodjournals.hematology.org
Blood Journals' Portfolio @bloodjournals.hematology.org · Sep 15
ELEVATE-ing clinical trial reporting in CLL buff.ly/FwUhcEw #hemesky
ELEVATE-ing clinical trial reporting in CLL
In this issue of Blood, Sharman et al1 report on the latest 6-year follow-up of the ELEVATE-TN trial, which previously reported the superiority of acalabru
buff.ly
1 3
Reposted by Kate Sears
sabcs.bsky.social
San Antonio Breast Cancer Symposium @sabcs.bsky.social · Sep 15
Breast Cancer in Young Women: When, Why, and How?
Melissa Troester, Kornelia Polyak, and Sherene Loi will address this question in an educational session at #SABCS25 (December 9-12). Learn more:
buff.ly/OB6T5Xs
@loisher.bsky.social
2 5
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 15
📌 Conclusion:
Neurotoxicity is a major survivorship challenge → need biomarkers, preventive strategies, multidisciplinary management.

#NeuroOncology #Neurotoxicity #CancerSurvivorship #MedEd
1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 15
💡 Management strategies
🔹CIPN: dose modification, duloxetine, lifestyle interventions
🔹RT: hippocampal-sparing, memantine
🔹IO: steroids, early recognition
1 1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 15
🧬 Mechanisms
🔹CIPN: axonal degeneration, ion channel changes, mitochondrial injury
🔹RT: neuroinflammation, vascular damage, neurogenesis impairment
🔹IO: autoimmunity & cytokine-driven CNS effects

🧪 Emerging biomarkers
➡️NfL, GFAP, imaging correlates
1 1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 15
🧾 Scope
➡️Peripheral + central neurotoxicity across chemo, RT, IO
➡️Covers CIPN, RT-induced cognitive decline, IO-related neuro events
1 1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 15
🧠 Neurotoxicity in Cancer Therapy
New review (Nat Rev Clin Oncol)

✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity
✅ Clinical recognition & biomarkers
✅ Prevention & management strategies

🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
1 2 4
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 12
📑 New ESMO CPG on Lymphomas

✅ Updated dx & staging recs
✅ 1L & r/r treatment algorithms
✅ Integration of CAR-T, bispecifics & BTKis

www.annalsofoncology.org/article/S092...
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
The treatment landscape for many lymphoma entities continues to evolve rapidly, with multiple recent approvals of novel non-chemotherapy (ChT)-based approaches. The following Clinical Practice Guideli...
www.annalsofoncology.org
1 1 2
Reposted by Kate Sears
weldeiry.bsky.social
Wafik S. El-Deiry, MD, PhD, FACP @weldeiry.bsky.social · Sep 12
Functional synapses between neurons and small cell lung cancer

www.nature.com/articles/s41...
Functional synapses between neurons and small cell lung cancer - Nature
Small cell lung cancer cells form functional synapses with glutamatergic neurons, receiving synaptic transmissions and deriving a proliferative advantage from these interactions.
www.nature.com
1 4
Reposted by Kate Sears
ascopost.bsky.social
The ASCO Post @ascopost.bsky.social · Sep 11
The @fda.gov has approved the gemcitabine intravesical system (Inlexzo) for adults with BCG-unresponsive non–muscle-invasive bladder cancer with CIS with/without papillary tumors.

In the SunRISe-1 trial: complete responses reported in 82%

ascopost.com/news/septemb...
1 2
Reposted by Kate Sears
cancergrace.bsky.social
cancergrace @cancergrace.bsky.social · Sep 11
🕯️ Today, we pause to remember the lives lost on September 11, 2001, and honor the courage of first responders, survivors, and families whose lives were forever changed.
May we continue to carry forward the lessons of unity, resilience, and compassion.
1 1 1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 11
🌟🟠 HER2 in mCRC
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟

✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive

#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch

ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
1 1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 10
✅ Surveillance underused despite curative potential
✅ IO-based combos in advanced HCC → OS >2 yrs
➡️ Ongoing need: prevention, early dx, biomarkers & access

#LiverCancer #GIOnc #Immunotherapy
www.jhep-reports.eu/article/S258...
Hepatocellular Carcinoma: Epidemiology, diagnosis and treatment
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and predominantly affects individuals with cirrhosis. While viral hepatitis has historically been the ma...
www.jhep-reports.eu
1
katesears.bsky.social
Kate Sears @katesears.bsky.social · Sep 10
🟢 Hepatocellular carcinoma (HCC) – 2025 global insights 🌍
New open-access review (Mauro, de Castro, Zeitlhoefler, Villanueva, Mazzaferro, Llovet et al.)

🔑 Highlights:
✅ 3rd leading cause of cancer death
✅ Etiology shift → viral ↓ | ALD & MASLD ↑
✅ Prevention: HBV vax + antivirals effective
1 1 2
Reposted by Kate Sears
sitcancer.bsky.social
Society for Immunotherapy of Cancer @sitcancer.bsky.social · Sep 10
We are excited to announce the 2026 SITC EU Immuno-Oncology Drug Development Summit. Coming Sept. 2026 in Lausanne, Switzerland. This program will discuss best practices for modern IO drug development & the next wave of IO therapeutics. Join the waitlist: t.co/JhPLTpSvdb 🧪
We are excited to announce the 2026 SITC EU Immuno-Oncology Drug Development Summit. Coming Sept. 2026 in Lausanne, Switzerland. This program will discuss best practices for modern IO drug development & the next wave of IO therapeutics. Join the waitlist: https://t.co/JhPLTpSvdb 🧪
1 1
Reposted by Kate Sears
trevorgraham.bsky.social
Trevor Graham @trevorgraham.bsky.social · Sep 10
Studying cancer evolution needs multi-region or single cell seq for phylogenetics, right? Amazingly (I think!) we found single-sample bulk methylation suffices, via analysis of "fluctuating methylation". In @nature.com today led by brilliant @calumgabbutt.bsky.social www.nature.com/articles/s41...
Fluctuating DNA methylation tracks cancer evolution at clinical scale - Nature
Cancer evolutionary dynamics are quantitatively inferred using a method, EVOFLUx, applied to fluctuating DNA methylation.
www.nature.com
7 39 92
Reposted by Kate Sears
snovelli.bsky.social
Silvana Novelli @snovelli.bsky.social · Sep 9
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies url: ashpublications.org/thehematolog...
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies
Ghobadi A, Aldoss I, Maude SL, . Phase 1/2 trial of anti-CD7 allogenic WU-CART-007 in patients with relapsed/refractory T-cell malignancies. Blood. Publish
ashpublications.org
1 1